---
reference_id: "PMID:41355925"
title: "Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report."
authors:
- Ma XT
- Yao GY
- Li JL
- Wang XC
- Ba Y
journal: World J Clin Oncol
year: '2025'
doi: 10.5306/wjco.v16.i11.112029
content_type: abstract_only
---

# Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report.
**Authors:** Ma XT, Yao GY, Li JL, Wang XC, Ba Y
**Journal:** World J Clin Oncol (2025)
**DOI:** [10.5306/wjco.v16.i11.112029](https://doi.org/10.5306/wjco.v16.i11.112029)

## Content

1. World J Clin Oncol. 2025 Nov 24;16(11):112029. doi:
10.5306/wjco.v16.i11.112029.

Perioperative immunotherapy combined with standard therapy for human epidermal 
growth factor receptor 2-positive locally advanced gastric cancer: A case 
report.

Ma XT(1), Yao GY(1), Li JL(2), Wang XC(1), Ba Y(3).

Author information:
(1)Department of Cancer Medical Center, Peking Union Medical College Hospital, 
Chinese Academy of Medical Sciences, Beijing 100032, China.
(2)Department of Medical Oncology, Changzhi Traditional Chinese Medicine 
Hospital, Changzhi 146000, Shanxi Province, China.
(3)Department of Cancer Medical Center, Peking Union Medical College Hospital, 
Chinese Academy of Medical Sciences, Beijing 100032, China. bayi@pumch.cn.

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive gastric 
cancer (GC) represents a distinct molecular cancer subtype that is often 
associated with a poor prognosis. While perioperative chemotherapy regimens are 
currently the primary recommendation for locally advanced HER2-positive GC, 
combination therapies incorporating immune checkpoint inhibitors are under 
active investigation.
CASE SUMMARY: The present case describes a patient with locally advanced 
HER2-positive GC who underwent perioperative treatment with chemotherapy 
combined with trastuzumab. Although significant tumor shrinkage was observed, 
surgical pathology results did not confirm the achievement of a pathological 
complete response. The current treatment strategies for advanced GC were also 
reviewed. Relevant case reports, retrospective studies, and prospective clinical 
trials were retrieved for analysis after searching the PubMed/MEDLINE, EMBASE, 
Cochrane Library, Web of Science, and American Society of Clinical 
Oncology/European Society for Medical Oncology conference abstracts between 2014 
and 2024.
CONCLUSION: Large-scale phase III clinical trials are needed to verify the 
efficacy of combined neoadjuvant treatment application for GC.

Â©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights 
reserved.

DOI: 10.5306/wjco.v16.i11.112029
PMCID: PMC12678912
PMID: 41355925

Conflict of interest statement: Conflict-of-interest statement: The authors 
declare that they have no competing interests.